Intensity-modulated radiation therapy for elderly patients (aged ≥75 years) with localized prostate cancer: Comparison with younger patients (aged <75 years)


Intensity-modulated radiation therapy for elderly patients (aged ≥75 years) with localized prostate cancer: Comparison with younger patients (aged <75 years)

Tanaka,Hidekazu; Nakashima,Yuka; Ito,Masaya; Yamaguchi,Takahiro; Esaki,Kae; Kamei,Shingo; Ishihara,Satoshi; Hayashi,Masahide; Ogawa,Shinichi; Goshima,Satoshi; Matsuo,Masayuki

doi:10.3892/mco.2019.1810

Intensity-modulated radiation therapy for elderly patients (aged ≥75 years) with localized prostate cancer: Comparison with younger patients (aged <75 years) Intensity-modulated radiation therapy for elderly patients (aged ≥75 years) with localized prostate cancer: Comparison with younger patients (aged <75 years)

Authors:
- Hidekazu Tanaka
- Yuka Nakashima
- Masaya Ito
- Takahiro Yamaguchi
- Kae Esaki
- Shingo Kamei
- Satoshi Ishihara
- Masahide Hayashi
- Shinichi Ogawa
- Satoshi Goshima
- Masayuki Matsuo
View Affiliations

Affiliations: Department of Radiology, Gifu University Hospital, Gifu 501-1194, Japan, Department of Urology, Kizawa Memorial Hospital, Minokamo, Gifu 505-8503, Japan, Department of Radiology, Kizawa Memorial Hospital, Minokamo, Gifu 505-8503, Japan
Published online on: February 18, 2019 https://doi.org/10.3892/mco.2019.1810
Pages: 476-480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the efficacy and safety of intensity‑modulated radiation therapy (IMRT) for elderly patients with prostate cancer (age ≥75 years) compared with younger patients (<75 years). The numbers of patients enrolled into the elderly and younger groups were 238 and 853, respectively. More than half of the patients in the elderly group were high‑risk, and the total risk of the elderly group was higher than that of younger group. The median follow‑up periods for the elderly and younger groups were 42 (range, 2‑108) and 49 (range, 2‑120) months, respectively. All patients were treated with IMRT at a dose of 74‑78 Gy with or without androgen‑deprivation therapy. The biochemical failure‑free rates (BFFRs) at 3‑year follow‑up for the elderly and younger groups were 93.3 and 95.7%, respectively; there was no significant difference between the 2 groups in regard to the BFFR. The clinical failure‑free rates (CFFR) at 3‑year follow‑up for the elderly and younger groups was 95.8 and 98.5%, respectively; the 2 groups did not differ significantly in regard to the CFFR. The cumulative incidence rates of gastrointestinal toxicity (grade ≥2) and genitourinary toxicity (grade ≥2) at 3‑year follow‑up were 10.5 and 1.3%, respectively; there was no significant difference between the elderly and younger groups. It was concluded that in prostate cancer patients aged 75 years or older, IMRT has a treatment effect equivalent to that in patients <75 years old; adverse events are also comparable.

View Figures

View References

1	GLOBOCAN 2012, . Estimated cancer incidence, mortality and prevalence worldwide in 2012. Leyon: World Health Organization; http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxOctober 31–2018
2	Projected cancer statistics, 2017. Tokyo, . Center for Cancer Control and Information Services, National Cancer Center. https://ganjoho.jp/en/public/statistics/short_pred.htmlOctober 31–2018
3	Cancer statistics in Japan 2016. Tokyo, . Center for Cancer Control and Information Services, National Cancer Center. https://ganjoho.jp/en/professional/statistics/brochure/2016_en.htmlOctober 31–2018
4	NCCN Guidelines for treatment of cancer by site, . Prostate Cancer. Fort Washington: National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfOctober 31–2018
5	Someya M, Hori M, Tateoka K, Nakata K, Takagi M, Saito M, Hirokawa N, Hareyama M and Sakata K: Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res (Tokyo). 56:122–127. 2015. View Article : Google Scholar
6	Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S and Amols H: Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 71:330–337. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yamazaki H, Nakamura S, Nishimura T, Yoshida K, Yoshioka Y, Koizumi M and Ogawa K: Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: Changing focus from rectal bleeding to detailed quality of life analysis. J Radiat Res (Tokyo). 55:1033–1047. 2014. View Article : Google Scholar
8	Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J and Kovarik J: Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol. 191:338–346. 2015. View Article : Google Scholar : PubMed/NCBI
9	Tanaka H, Yamaguchi T, Hachiya K, Kamei S, Ishihara S, Hayashi M, Ogawa S, Nishibori H, Goshima S and Matsuo M: Treatment outcomes and late toxicities of intensity-modulated radiation therapy for 1091 Japanese patients with localized prostate cancer. Rep Pract Oncol Radiother. 23:28–33. 2018. View Article : Google Scholar : PubMed/NCBI
10	Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B and Zelefsky MJ: Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 117:1429–1437. 2011. View Article : Google Scholar : PubMed/NCBI
11	Bechis SK, Carroll PR and Cooperberg MR: Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 29:235–241. 2011. View Article : Google Scholar : PubMed/NCBI
12	Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS and Yao SL: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 300:173–181. 2008. View Article : Google Scholar : PubMed/NCBI
13	Japan ALTF: Tokyo. Ministry of Health, Labour and Welfare, Japan, . 2016, http://www.mhlw.go.jp/english/database/db-hw/lifetb16/index.html
14	D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, et al: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 95:281–286. 2002. View Article : Google Scholar : PubMed/NCBI
15	Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH and Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 65:965–974. 2006. View Article : Google Scholar : PubMed/NCBI
16	Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Bethesda, . National Institutes of Healths, Department of Health and Human Services. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfOctober 31–2018
17	Wilcox SW, Aherne NJ, McLachlan CS, McKay MJ, Last AJ and Shakespeare TP: Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: A comparison of Australian series. J Med Imaging Radiat Oncol. 59:125–133. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zelefsky MJ, Poon BY, Eastham J, Vickers A, Pei X and Scardino PT: Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer. Radiother Oncol. 118:85–91. 2016. View Article : Google Scholar : PubMed/NCBI
19	Hayashi S, Tanaka H, Kajiura Y, Ohno Y and Hoshi H: Stereotactic body radiotherapy for very elderly patients (age, greater than or equal to 85 years) with stage I non-small cell lung cancer. Radiat Oncol. 9:1382014. View Article : Google Scholar : PubMed/NCBI
20	Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, Dipaola RS and Lu-Yao GL: Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 101:1280–1283. 2009. View Article : Google Scholar : PubMed/NCBI